Related Experiment Video
Updated: May 1, 2026
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 17, 2014
Airway inflammation in chronic obstructive pulmonary disease
Nikolaos Angelis1, Konstantinos Porpodis1, Paul Zarogoulidis1
11 Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece ; 2 Cardiology Department, "Saint Luke" Private Clinic, Thessaloniki, Panorama, Greece ; 3 Internal Medicine Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece ; 4 Surgery Department (NHS), University General Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece ; 5 2nd Cardiac Surgery Department, "Evangelismos" General Hospital, Athens, Greece ; 6 Oncology Department, "Saint Luke" Private Clinic, Thessaloniki, Panorama, Greece.
Biomarkers in biological fluids and exhaled air are crucial for understanding chronic obstructive pulmonary disease (COPD) inflammation. Identifying specific COPD biomarkers may enable targeted therapies for improved patient outcomes.
Area of Science:
- Pulmonology
- Inflammatory Diseases
- Biomarker Discovery
Background:
- Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory airway disease with increasing incidence and mortality.
- Pathophysiology involves chronic airway inflammation, mucus hypersecretion, airway stenosis, and pulmonary emphysema, often linked to smoking.
- Noninvasive techniques for assessing inflammatory mediators are gaining importance in managing airway diseases.
Purpose of the Study:
- To explore the role of noninvasive biomarkers in characterizing the inflammatory patterns of COPD.
- To identify clinically exploitable biomarkers associated with specific COPD phenotypes.
- To investigate the potential of therapeutic interventions targeting these biomarkers for personalized COPD treatment.
Main Methods:
- Evaluation of various markers in biological fluids.
- Analysis of biomarkers in exhaled air.
- Assessment of biomarkers as research tools and for clinical practice integration.
Main Results:
- Several noninvasive biomarkers are under intense evaluation for COPD.
- Some biomarkers have entered clinical practice, while others are still research tools.
- Discovery of clinically relevant biomarkers for specific COPD phenotypes is of significant scientific interest.
Conclusions:
- Noninvasive biomarkers are essential for understanding COPD pathophysiology and inflammatory patterns.
- Biomarker discovery holds promise for developing targeted therapies based on individual COPD phenotypes.
- Future COPD therapeutics may focus on phenotype-specific treatments guided by biomarker analysis.
Related Concept Videos
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
01:23Chronic Obstructive Pulmonary Disease I: Introduction
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:28Asthma I: Introduction